The company will use the grant proceeds to conduct research that will allow for rapid labeling and purification of specific lineage restricted cells (LRCs) in cultures of differentiating human embryonic stem cells. If successful, the research will help the company more rapidly develop new regenerative therapies for a variety of indications including cardiovascular disease as well for commercialization of the LRCs and their peptide-targeting agents as research reagents.
William Caldwell, IV, chairman and CEO of Advanced Cell Technology, said: “We are pleased that prestigious institutions such as the National Institutes of Health (NIH) continue to recognize and support our R&D programs. We will continue to work with the NIH and other organizations to raise awareness and capital to support our ongoing research and commercialization projects without diluting shareholder value.”